Case Details
- Citation: [2000] SGHC 53
- Court: High Court of the Republic of Singapore
- Decision Date: 31 March 2000
- Coram: Tay Yong Kwang JC
- Case Number: Suit 1762/1998
- Claimants / Plaintiffs: Institut Pasteur; Pasteur Sanofi Diagnostics
- Respondent / Defendant: Genelabs Diagnostics Pte Ltd; Nagase Singapore (Pte) Ltd
- Counsel for Claimants: Tony Yeo, Gerald Koh and Celeste Ang (Drew & Napier)
- Counsel for Respondent: Tan Tee Jim S C, Jason Chan and Tan Wee Meng (Allen & Gledhill)
- Practice Areas: Intellectual Property; Patent Infringement; Setting aside of arbitral awards
Summary
The judgment in Institut Pasteur and Another v Genelabs Diagnostics Pte Ltd and Another [2000] SGHC 53 represents a seminal exploration of patent validity and infringement within the burgeoning field of biotechnology in Singapore. The dispute centered on European Patent No. 0 239 425, which concerned the HIV-2 retrovirus, its antigenic components, and nucleic acid sequences. The First Plaintiff, a renowned French non-profit foundation, and the Second Plaintiff, its exclusive licensee, sought to protect their intellectual property against the unauthorized manufacture and distribution of diagnostic kits by the Defendants. The case is particularly significant for its application of the transitional provisions of the Patents Act (Cap 221, 1995 Rev Ed), which preserved rights granted under the repealed Registration of United Kingdom Patents Act.
The High Court was tasked with resolving a multi-faceted challenge to the Patent's validity. The Defendants contended that the Patent lacked novelty and an inventive step, relying on a suite of prior art documents that allegedly anticipated the Plaintiffs' discovery. Furthermore, the Defendants raised issues of "classical insufficiency," arguing that the Patent did not disclose the invention in a manner clear and complete enough for it to be performed by a person skilled in the art. The Court's analysis required a deep dive into the "notional skilled addressee" in the context of retrovirology and molecular biology, balancing the technical complexity of the invention against the legal standards for patentability.
Ultimately, the Court upheld the validity of the Patent and found that both Defendants had infringed the Plaintiffs' rights. However, the judgment introduced a critical distinction regarding remedies. While the First Defendant was found fully liable, the Second Defendant successfully invoked the statutory defense under Section 69(1) of the Patents Act, proving that at the date of the infringement, it was not aware and had no reasonable grounds for supposing that the Patent existed. This resulted in a judgment for the Plaintiffs but with a significant limitation on the financial recovery from the Second Defendant, highlighting the importance of the "innocent infringer" doctrine in Singapore law.
The doctrinal contribution of this case extends to the interpretation of Section 116(3) of the Patents Act, the application of the Windsurfing test for inventive step, and the Catnic/Improver precepts for purposive construction of patent claims. By dismissing the Defendants' counterclaim for revocation, the Court reinforced the robustness of biotechnology patents in Singapore, provided they meet the rigorous standards of disclosure and non-obviousness at their priority date.
Timeline of Events
- 26 March 1981: An agreement was signed between the parties (later renewed on 11 July 1990) establishing certain obligations regarding the registration of relevant documents.
- 19 December 1985: A key date in the development of the underlying technology, as referenced in the factual matrix regarding prior disclosures.
- 22 January 1986: The priority date for the European Patent designating the United Kingdom (No. 0 239 425).
- 22 January 1987: The filing date of the application for the Patent.
- 2 November 1989: The European Patent was formally granted to Institut Pasteur.
- 14 January 1990: A date relevant to the ongoing commercial and scientific context of the HIV-2 retrovirus research.
- 15 January 1993: The Patent was re-registered in Singapore under the Registration of United Kingdom Patents Act, assigned number 9190285-8.
- 23 December 1993: Further correspondence or events occurred regarding the commercialization or monitoring of the technology.
- 25 February 1994: A date cited in the procedural or factual history regarding the interaction between the Plaintiffs and the Defendants.
- 23 February 1995: The Patents Act (Cap 221) came into operation in Singapore, introducing transitional provisions under Section 116(3).
- 30 June 1997: Events occurred relating to the alleged infringing activities or the discovery thereof by the Plaintiffs.
- 30 June 1998: A significant date in the lead-up to litigation, involving the monitoring of the Defendants' market activities.
- 11 July 1998: Specific instances of alleged infringement or notice were recorded.
- 17 July 1998: Further factual developments regarding the distribution of the accused diagnostic kits.
- 13 August 1998: The Plaintiffs continued to gather evidence of the Defendants' activities in Singapore.
- 11 September 1998: Final pre-action steps were taken.
- 5 October 1998: The Plaintiffs filed the Writ of Summons (Suit 1762/1998), commencing the legal proceedings.
- 20 April 1999: Procedural milestones during the litigation phase.
- 18 February 2000: The conclusion of the hearing or final submissions before the Court.
- 31 March 2000: Judgment was delivered by Tay Yong Kwang JC.
What Were the Facts of This Case?
The First Plaintiff, Institut Pasteur, is a non-profit private foundation registered in France, globally recognized for its research into infectious diseases. The Second Plaintiff, Pasteur Sanofi Diagnostics, is a French company and the exclusive licensee of the Patent in suit. The First Defendant, Genelabs Diagnostics Pte Ltd, is a Singapore-incorporated company involved in the manufacture of diagnostic products. The Second Defendant, Nagase Singapore (Pte) Ltd, is also a Singapore company that acted in a capacity that involved the distribution or keeping of the accused products.
The core of the dispute was European Patent No. 0 239 425 ("the Patent"), which was granted on 2 November 1989 and re-registered in Singapore on 15 January 1993. The Patent related to the HIV-2 retrovirus, a virus capable of inducing Acquired Immune Deficiency Syndrome (AIDS). Specifically, the Patent covered the isolated virus, its antigenic components (proteins), and its nucleic acid sequences (DNA/RNA). These components are essential for creating diagnostic kits that can detect the presence of HIV-2 antibodies in human blood, a critical tool for public health and clinical diagnosis.
The Plaintiffs alleged that the Defendants had infringed the Patent by making, disposing of, offering to dispose of, using, importing, and keeping HIV-2 diagnostic kits in Singapore. These kits utilized the specific antigens and sequences protected by the Patent. The Plaintiffs sought an injunction, an inquiry as to damages or an account of profits, and the delivery up or destruction of the infringing articles. They argued that the Patent was valid and that the Defendants' activities fell squarely within the scope of the claims.
The Defendants mounted a vigorous defense, challenging the validity of the Patent on several grounds. They argued that the invention was not new (lack of novelty) and was obvious to a person skilled in the art (lack of inventive step) at the priority date of 22 January 1986. They relied on numerous prior art documents, including scientific papers and earlier patent applications, which they claimed disclosed the HIV-2 virus or similar retroviruses before the Plaintiffs' priority date. The Defendants also contended that the Patent was "insufficient," meaning it did not provide enough information for a scientist to replicate the invention without undue burden.
A significant factual sub-issue concerned the Second Defendant's knowledge of the Patent. Nagase Singapore (Pte) Ltd argued that it was an innocent infringer. It claimed that it was unaware of the Patent's existence in Singapore and had no reason to suspect that the diagnostic kits it was dealing with were protected by a patent held by Institut Pasteur. This factual determination was crucial for the application of Section 69(1) of the Patents Act.
The trial involved extensive expert evidence from both sides, as the Court had to navigate complex biological data, including protein molecular weights (e.g., p24, gp36, gp105/140) and genetic sequencing. The Court had to determine whether the "LAV-II" virus described in the Patent was truly a new discovery or merely a variation of known viruses like HIV-1 or SIV (Simian Immunodeficiency Virus). The procedural history included an amendment to the Defendants' Particulars of Objection and a counterclaim for the revocation of the Patent, which the Court ultimately had to decide alongside the primary infringement claim.
What Were the Key Legal Issues?
The litigation raised several critical legal issues that required the Court to interpret both the old and new patent regimes in Singapore. The primary issues were as follows:
- Validity of the Patent (Novelty): Whether the invention claimed in the Patent was anticipated by prior art available before 22 January 1986. This involved the application of the test in General Tire & Rubber Co. v Firestone Tyre & Rubber Co Ltd [1972] RPC 457.
- Validity of the Patent (Inventive Step): Whether the invention was obvious to a person skilled in the art, applying the four-step test from Windsurfing International Inc v Tabur Marine (Great Britain) Ltd [1985] RPC 59.
- Sufficiency of Disclosure: Whether the Patent complied with Section 25 of the Patents Act by disclosing the invention clearly and completely enough for a skilled person to perform it.
- Infringement: Whether the Defendants' diagnostic kits fell within the scope of the Patent's claims, necessitating a purposive construction of those claims as per Catnic Components Ltd v Hill & Smith Ltd [1982] RPC 183.
- Statutory Defense for Innocent Infringement: Whether the Second Defendant could rely on Section 69(1) of the Patents Act to avoid an award of damages or an account of profits.
- Transitional Provisions: The effect of Section 116(3) of the Patents Act on patents registered under the repealed Registration of United Kingdom Patents Act.
- Laches and Acquiescence: Whether the Plaintiffs' delay in bringing the suit (from the date of registration in 1993 to the writ in 1998) barred them from seeking equitable relief.
How Did the Court Analyse the Issues?
The Court's analysis began with the transitional framework. Tay Yong Kwang JC noted that while the Patent was registered under the old Registration of United Kingdom Patents Act, Section 116(3) of the Patents Act 1994 preserved such patents as if they were granted under the new Act. This meant that the validity of the Patent could be challenged under Section 82(1)(a) of the current Act, which is modeled on the UK Patents Act 1977. The onus of proving invalidity rested squarely on the Defendants.
In addressing Novelty, the Court applied the strict test from General Tire & Rubber Co. v Firestone Tyre & Rubber Co Ltd [1972] RPC 457. The Court emphasized that for a prior publication to anticipate a claim, it must contain "clear and unmistakable directions" to do what the patentee claims to have invented (at [187]). The Defendants pointed to several prior disclosures, but the Court found they were either distinct from the HIV-2 virus or lacked the specific isolated characteristics and sequences claimed in the Patent. The Court held that the prior art did not enable the skilled person to arrive at the invention without further research and discovery.
The Inventive Step analysis followed the Windsurfing test. The Court first identified the inventive concept embodied in the Patent—the isolation and characterization of a second, distinct human immunodeficiency retrovirus (HIV-2). Second, it assumed the mantle of the "notional skilled person," described as a person of standard competence in the field of retrovirology but lacking "inventive imagination" (at [193]). Third, it identified the differences between the prior art and the inventive concept. Fourth, it asked whether those differences were obvious. The Court concluded that the leap from HIV-1 to the isolation of HIV-2 was not a matter of routine experimentation but required significant scientific insight, thus satisfying the requirement for an inventive step.
Regarding Sufficiency, the Court referred to Biogen Inc. v Medeva PLC [1997] RPC 1. The Defendants argued that the Patent did not provide enough detail to reproduce the virus or the antigens. However, the Court held that disclosure under Section 25 of the Patents Act does not require "minute, step by step directions" (at [202]). The skilled person is expected to use their common general knowledge and a reasonable degree of skill. Since the virus had been deposited in a recognized culture collection (the CNCM in Paris), the disclosure was deemed sufficient.
The Infringement analysis required the Court to construe the claims. Following Catnic Components Ltd v Hill & Smith Ltd [1982] RPC 183, the Court adopted a purposive rather than a literal construction. It asked whether the skilled person would understand that the patentee intended strict compliance with a particular descriptive word or phrase. The Court also utilized the "Hoffmann questions" from Improver Corporation v Remington Consumer Products Ltd [1990] FSR 181 to determine if variations in the Defendants' kits still infringed the "pith and marrow" of the invention. The Court found that the Defendants' kits used antigens that were functionally and structurally equivalent to those described in the Patent, thereby constituting infringement.
A pivotal part of the judgment was the Section 69(1) Defense raised by the Second Defendant. The Court examined whether Nagase Singapore (Pte) Ltd had "reasonable grounds for supposing that the patent existed." The Court noted that the mere registration of a patent in the public register does not automatically preclude a finding of innocence under Section 69(1). The Second Defendant provided evidence that it was a distributor and had no reason to investigate the patent status of the kits it handled. The Court accepted this, holding that while the Second Defendant was liable for infringement, it was protected from a claim for damages or an account of profits.
Finally, the Court dismissed the defenses of Laches and Acquiescence. Citing Syed Ali Redha Alsagoff v Syed Salim Alhadad [1996] 3 SLR 410, the Court held that for acquiescence to succeed, there must be a "dishonest standing by" or a representation that led the Defendants to believe the Plaintiffs would not enforce their rights. The mere lapse of time between 1993 and 1998 did not meet this threshold, especially as the Plaintiffs were active in protecting their rights globally.
What Was the Outcome?
The Court delivered a comprehensive victory for the Plaintiffs on the merits of the case, while providing a statutory shield for the Second Defendant regarding financial penalties. The operative order of the Court was as follows:
"I therefore gave judgment for both Plaintiffs against the Defendants except that no damages or account of profits would be ordered against the Second Defendant by virtue of Section 69(1). The Counterclaim was accordingly dismissed." (at [232])
The specific orders granted by Tay Yong Kwang JC included:
- Declarations: A declaration that European Patent No. 0 239 425 (Singapore Patent No. 9190285-8) was valid and had been infringed by both the First and Second Defendants.
- Injunctions: The Defendants were restrained from further infringing the Patent, including the manufacture, sale, or importation of the infringing HIV-2 diagnostic kits.
- Financial Remedies: An inquiry as to damages or an account of profits was ordered against the First Defendant. However, pursuant to Section 69(1) of the Patents Act, no such financial remedy was ordered against the Second Defendant.
- Delivery Up: The Defendants were ordered to deliver up or destroy all infringing articles in their possession.
- Costs: The First Defendant was ordered to pay the full costs of both Plaintiffs for the Claim and the Counterclaim. The Second Defendant, having succeeded on the Section 69(1) issue, was ordered to pay only 90% of the costs of the Claim and the Counterclaim.
The dismissal of the Counterclaim for revocation was a significant result, as it confirmed the Patent's status in Singapore for its remaining term. The Court's decision to award 90% costs against the Second Defendant reflected the fact that the Second Defendant had failed on the primary issues of validity and infringement, which occupied the bulk of the trial, but had succeeded on a specific statutory defense.
Why Does This Case Matter?
This case is a cornerstone of Singapore's patent jurisprudence, particularly in the life sciences sector. Its significance can be analyzed across three main dimensions: the protection of biotechnology, the interpretation of transitional law, and the application of the innocent infringer defense.
First, the judgment affirmed that biotechnology inventions, even those involving naturally occurring viruses, are patentable in Singapore if they are isolated and characterized in a way that provides a technical contribution. By upholding the HIV-2 patent, the Court sent a clear signal that the Singapore legal system would protect high-stakes medical research. The Court's refusal to find the invention obvious, despite the existence of HIV-1, recognized the significant scientific hurdle involved in identifying and isolating a new viral strain. This provided much-needed certainty for pharmaceutical and diagnostic companies operating in Singapore.
Second, the case clarified the transitional provisions of the Patents Act. Many patents in Singapore during the late 1990s were "re-registered" UK patents. Tay Yong Kwang JC's analysis of Section 116(3) confirmed that these patents are treated as if they were granted under the 1994 Act, making them subject to the same validity challenges and infringement tests. This harmonized the treatment of old and new patents, ensuring a consistent legal standard across the entire Singapore patent register.
Third, the application of Section 69(1) remains one of the most detailed treatments of the "innocent infringer" defense in Singapore. The Court's finding that the Second Defendant was an innocent infringer, despite the Patent being on the public register, is a crucial precedent for distributors and middle-men in the supply chain. It establishes that the "reasonable grounds for supposing" test is a factual inquiry into the specific circumstances of the defendant, rather than a strict rule of constructive notice based on the existence of the register. This balance prevents the patent system from becoming overly punitive for parties who are not the primary manufacturers and who act in good faith.
Furthermore, the Court's adoption of the purposive construction (Catnic) and the Improver questions solidified these English law principles as part of the Singapore patent landscape. This alignment with international standards made Singapore a more attractive forum for intellectual property litigation, as practitioners could rely on a well-understood and predictable framework for claim construction.
Finally, the case highlights the importance of expert evidence in complex litigation. The Court's ability to parse through 89 pages of technical data and scientific testimony demonstrates the judiciary's competence in handling "heavy" IP disputes. For practitioners, the case serves as a reminder that success in patent litigation often hinges on the ability to translate complex science into the "notional skilled person" framework that the Court uses to judge novelty and inventive step.
Practice Pointers
- Due Diligence for Distributors: Distributors and importers should conduct thorough patent searches or obtain indemnities from manufacturers. While the Section 69(1) defense was successful for the Second Defendant here, it is a fact-sensitive defense that may not be available if there are any "red flags" regarding patent protection.
- Sufficiency of Disclosure: When drafting or defending biotech patents, ensure that biological deposits (like those at the CNCM) are properly referenced. This can be a decisive factor in overcoming "classical insufficiency" arguments.
- Claim Construction Strategy: Practitioners should prepare for a "purposive construction" analysis. Arguments should focus on how the "notional skilled person" would view the claims, rather than relying on a literalist interpretation of the text.
- Transitional Patents: For patents registered under the old UK re-registration regime, always check the status under Section 116(3). These patents are fully integrated into the current Act and are vulnerable to the same revocation grounds as newly granted patents.
- Laches is a High Bar: Do not rely on a plaintiff's delay in suing as a primary defense unless there is clear evidence of a representation or "dishonest standing by." The Singapore courts are reluctant to bar statutory patent rights based on mere delay.
- Costs Allocation: Be aware that succeeding on a minor issue (like the Section 69 defense) may only result in a small reduction in costs (e.g., 10%) if the bulk of the trial was spent on issues where the party failed.
Subsequent Treatment
The decision in Institut Pasteur v Genelabs has been consistently cited in Singapore as a leading authority on the validity of biotechnology patents and the application of the Windsurfing test for inventive step. Its treatment of Section 69(1) remains a primary reference point for the "innocent infringer" defense. Later cases have followed its approach to purposive claim construction, reinforcing the Catnic/Improver framework in the Singapore High Court and Court of Appeal. The ratio regarding the isolation of viral strains as a patentable inventive step continues to inform the Examination Guidelines of the Intellectual Property Office of Singapore (IPOS).
Legislation Referenced
- Patents Act (Cap 221, 1995 Rev Ed), Sections 1, 2, 13(1), 14, 14(2), 14(3), 15, 18, 23, 25, 25(4), 25(5), 66, 66(1), 66(1)(a), 66(1)(b), 67(1), 69, 69(1), 75, 80, 82(1)(a), 82(3), 113(1), 116(3)
- Registration of United Kingdom Patents Act (Repealed), Section 11
- Limitation Act (Cap 163), Section 32
- United Kingdom Patents Act 1977
- United Kingdom Patents Act 1949
Cases Cited
- Applied: General Tire & Rubber Co. v Firestone Tyre & Rubber Co Ltd [1972] RPC 457
- Considered/Referred to:
- Windsurfing International Inc v Tabur Marine (Great Britain) Ltd [1985] RPC 59
- Catnic Components Ltd v Hill & Smith Ltd [1982] RPC 183
- Improver Corporation v Remington Consumer Products Ltd [1990] FSR 181
- Biogen Inc. v Medeva PLC [1997] RPC 1
- Syed Ali Redha Alsagoff v Syed Salim Alhadad [1996] 3 SLR 410
- Scan Electronics (S) Pte Ltd v Syed Ali Redha Alsagoff [1997] 2 SLR 13
- British and Malayan Trustees Ltd v Sindo Realty Pte Ltd [1998] 2 SLR 495
- Asahi Kasei Kogyo KK’s Application [1991] RPC 485
- PLG Research Ltd v Ardon International Ltd [1993] FSR 197
- Merrell Dow Pharmaceutical Inc v Norton & Co Ltd [1995] RPC 233
- Van der Lely N.V. v Bamfords Ltd [1961] RPC 296
- Van der Lely N.V. v Ruston’s Engineering Co Ltd [1985] RPC 461
- Valensi v British Radio Corporation [1973] RPC 337
- Mentor Corp. v Hollister Inc [1993] RPC 7
- Kalman v PCL Packaging (UK) Ltd [1982] FSR 406
- Lowndes’ Patent (1928) 45 RPC 48